Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection

Dwight Egan, Chief Executive Officer of Co-Diagnostics

“Emerging infectious disease threats are a constant reminder of why we built Co-Diagnostics and why we\'ve continued to invest in the capabilities needed to respond quickly when new challenges arise”

Dwight Egan, Chief Executive Officer of Co-Diagnostics

“Our response to COVID-19 demonstrated our ability to rapidly develop and commercialize molecular diagnostics, and we\'ve built on that foundation through our work with mpox, Ebola and other infectious diseases. Today, our integrated platform combines our patented Co-Primers® technology, sample-preparation capabilities and in-house oligonucleotide manufacturing in the United States and India, giving us greater control over the development and production of new tests.”

Dwight Egan, Chief Executive Officer of Co-Diagnostics

“Sputum is a key specimen type for pneumonic plague, and our point-of-care tuberculosis program has given us experience preparing sputum samples for bacterial PCR testing. We designed the Co-Dx PCR platform to bring molecular testing closer to patients, particularly in settings where access to centralized laboratories may be limited. While we have not initiated development of a plague-specific assay, we believe our technology and experience provide a foundation to respond should the need arise.”